Moleculin 8-K：Annamycin 将于9月三场科学会议展示新数据，关键AACR胰腺癌摘要仍处保密期、9月25日才发布

----- ex_1015491.htm -----
EX-99.1
2
ex_1015491.htm
EXHIBIT 99.1
ex_1015491.htm
Exhibit 99.1
Moleculin to Showcase New Annamycin Data at AACR Conference on
Pancreatic Cancer and Two European Scientific Meetings
Presentations examine where Annamycin concentrates in the body, how it
targets topoisomerase II, and its antitumor activity in pancreatic cancer
HOUSTON, September 14, 2026 /PRNewswire/ -- Moleculin Biotech, Inc.
(Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development.
The three presentations address distinct questions about Annamycin: where it concentrates in the body, how it kills cancer cells, and whether it can also enlist the immune system to do so. Together they inform the Company’s development of Annamycin in hard-to-treat cancers.
Title:
“
Antitumor activity of ANNAMYCIN, a highly effective lipophilic DNA-binding drug: Impact of its organotropism
”
Author/Presenter:
Waldemar Priebe, PhD, UT MD Anderson Cancer Center
Congress:
XIII Congress of the Polish Medical Diaspora
Dates:
September 9–12, 2026
Location:
Wroclaw, Poland
Annamycin’s lipophilic structure drives it to concentrate in specific tissues rather than distribute uniformly. Dr. Priebe’s presentation examines how that distribution relates to the antitumor activity observed across preclinical models, and what it may mean for treating tumors in those tissues.
Title:
“
Organotropism-guided exploration of anticancer properties of Annamycin (naxtarubicin), a potent topoisomerase II targeting agent
”
Author/Presenter:
Waldemar Priebe, PhD, UT MD Anderson Cancer Center
Event:
Invited Lecture at the Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
Date:
September 14, 2026
Location:
Wroclaw, Poland
This invited lecture extends the same line of inquiry to mechanism, examining how Annamycin’s tissue distribution interacts with its inhibition of topoisomerase II, the enzyme target through which anthracyclines produce DNA damage in dividing cells.
Title:
“
Turning cold pancreatic tumors hot: Antitumor activity of Annamycin is partially mediated by CD8+ T cell cytotoxicity
”
Author/Presenter:
Angela T. Alistar, MD, Morristown Medical Center, Atlantic Health System / Carol G. Simon Cancer Center
Congress:
AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development
Dates:
September 25–28, 2026
Location:
Hilton San Diego Bayfront, San Diego, California
The abstract for this presentation remains under embargo until publication. Moleculin expects to report on the findings when the abstract is published, as described below.
Abstracts selected for presentation at the AACR Conference on Pancreatic Cancer will be published as a supplement to the September 15, 2026 issue of
Cancer Research
on September 25, 2026, at 1:00 p.m. ET.
“Annamycin’s ability to concentrate in specific tissues is one of the properties that most distinguishes it from currently prescribed anthracyclines, and it is the through-line across these presentations,” said Walter Klemp, Chairman, President and Chief Executive Officer of Moleculin. “Having this work presented by leading investigators, and accepted at an AACR conference, reflects the breadth of scientific interest in Annamycin beyond our lead indication in AML.”
These presentations run alongside Moleculin’s lead clinical program, the ongoing MIRACLE trial evaluating AnnAraC in patients with relapsed or refractory acute myeloid leukemia (AML). MIRACLE remains the Company’s primary development focus and the basis of its near-term milestones.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company has begun the MIRACLE (
M
olecul
i
n
R
/R AML
A
nnAraC
Cl
inical
E
valuation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit
www.moleculin.com
and connect on
X
,
LinkedIn
and
Facebook
.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML and the expectation that interim efficacy trends observed in a limited patient population will be confirmed in the full study population (the interim results presented are based on a small sample size (n=45), have not achieved statistical significance, and may not be predictive of results from the completed trial). Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

----- mbrx20260911_8k.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
September 14, 2026
MOLECULIN BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
001-37758
47-4671997
(State or Other Jurisdiction of
Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification
No.)
5300 Memorial Drive
,
Suite 950
,
Houston
,
TX
77007
(Address of principal executive offices and zip code)
(
713
)
300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock
, par value $.001 per share
MBRX
The
NASDAQ
Stock Market LLC
Item 7.01
Regulation FD Disclosure
On September 14, 2026, Moleculin Biotech, Inc. (the “Company”), issued a press release which announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development.
The three presentations address distinct questions about Annamycin: where it concentrates in the body, how it kills cancer cells, and whether it can also enlist the immune system to do so. Together they inform the Company’s development of Annamycin in hard-to-treat cancers.
A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No.
Description
99.1
Press Release dated September 14, 2026
104
Cover page Interactive Data File (formatted as Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOLECULIN BIOTECH, INC.
Date:
September 14, 2026
By:
/s/ Jonathan P. Foster
Jonathan P. Foster